You are now leaving the Lilly Medical Education website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical Education.
Mode of Disease - Bruton Tyrosine Kinase (BTK) in B Cell Malignancies
This short video provides an overview of the role of BTK inhibition in B cell malignancies.
Date of Last Review: August 2, 2024
Document Number: VV-MED-162377
Related Resources
This slide deck provides information on covalent and non-covalent (reversible) BTK inhibition in B-cell malignancies, and a growing unmet need of resistance to covalent BTK inhibition.
This slide deck provides a deeper dive on non-covalent (reversible) BTK inhibition in B-cell malignancies, and a growing unmet need of resistance to covalent BTK inhibition.
The slide deck for HCPs will provide an understanding of mechanisms of Bruton's tyrosine kinase inhibition in CLL.
Infographic for HCPs reviewing BTK inhibition and pharmacologic properties for covalent and non-covalent BTK inhibitors.
Please rate your satisfaction with the content on the following statements:
Very Dissatisfied
Dissatisfied
Neutral
Satisfied
Very Satisfied